On Friday, the leaders of the Senate and House health committees released a discussion draft of bipartisan legislation reauthorizing the Food and Drug Administration user fee agreements. The Food and Drug Administration (FDA) Reauthorization Act of 2017 renews FDA's authority to collect user fees from the makers of prescription brand drugs, medical devices, generic drugs and biosimilars, and several vital programs at the FDA.The 2012 prescription drug user fee amendments (PDUFA), medical device
Read More
- Skip to main content
- Skip to secondary menu
- Skip to primary sidebar
- Skip to secondary sidebar
- Skip to footer
Footer
